Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians

View larger version (25K): [in a new window]   Figure 1. Meta-analysis of the absolute risk reduction of lipid-lowering as primary prevention in patients with diabetes. Note that the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is not included in this figure because data on absolute risk reduction in the diabetes subgroup were not available. AFCAPS/TexCAPS = Air Force Coronary Atherosclerosis Prevention Study/Texas Coronary Atherosclerosis Prevention Study; ASCOT-LLA = Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm; HHS = Helsinki Heart Study; HPS-1 = Heart Protection Study (primary prevention arm); PROSPER-1 = Prospective Study of Pravastatin in the Elderly at Risk (primary prevention arm).

View larger version (33K): [in a new window]   Figure 2. Meta-analysis of the absolute risk reduction of lipid-lowering as secondary prevention in patients with diabetes. The meta-analysis was done by using a random-effects model because of between-study heterogeneity (P = 0.026). 4S = Scandinavian Simvastatin Survival Study; CARE = Cholesterol and Recurrent Events trial; HPS-2 = Heart Protection Study (secondary prevention arm); LIPID = Long-term Intervention with Pravastatin in Ischemic Disease trial; LIPS = Lescol Intervention Prevention Study; Post-CABG = Post–Coronary Artery Bypass Graft trial; PROSPER-2 = Prospective Study of Pravastatin in the Elderly at Risk (secondary prevention arm); VA-HIT = Veterans Administration High-Density Lipoprotein Cholesterol Intervention Trial.